MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

Sign-in
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

MOA

MOA

MAVENCLAD™ PREDOMINATELY AFFECTS LYMPHOCYTES WHILE CELLS OF THE INNATE IMMUNE SYSTEM ARE LESS AFFECTED1*†

MS pathology involves a complex chain of events in which different immune cell types, including autoreactive T and B cells, play a key role. While MAVENCLAD’s mechanism of action is not fully understood, its predominant effect on lymphocytes is thought to interrupt the cascade of immune events central to MS.

Pharmacodynamics

 

Reduction in Lymphocytes

Lymphocyte Recovery

  

 

MAVENCLAD has been shown to exert long-lasting effects by preferentially targeting lymphocytes and the autoimmune processes involved in MS

- Median lymphocyte counts: returned to the normal range at week 84, approximately 30 weeks (7 months) after the last dose

- 75% of lymphocyte counts: returned to the normal range by week 144, approximately 90 weeks (21 months) after the last dose

  

Lymphocyte recovery

MOA

Cells of the innate immune system are less affected than cells of the adaptive immune system

MAVENCLAD has an estimated terminal half-life of 23h‡  

* Clinical significance is unknown.

† MAVENCLAD’s predominant effect on lymphocytes may be explained by variations in the expression levels of deoxycytidine kinase (DCK) and 5'-nucleotidase (5'-NTase) between immune cell subtypes.

‡ Based on pooled population pharmacokinetic data. Drug accumulation does not occur after once daily dosing as this half-life only accounts for a small portion of the AUC.

Learn more about MAVENCLAD

 

Demonstrated efficacy

Monitoring

Safety and tolerability profile

  

 

Explore MAVENCLAD’s efficacy.

Learn more

Discover MAVENCLAD’s monitoring.

Learn more

Learn about MAVENCLAD’s safety and
tolerability profile.

Learn more

  
Footnotes and references
  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our Cookie policy.

OK, GOT IT

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.

lightbox image